LSI USA '25 Almost at Capacity: Register Today arrow-icon
Jan 24, 2025

The Weekly Recap 1/24/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

The Weekly Recap 1/24/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

Weekly Recap 16_9 - 1.24.2025

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure FDA clearance, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).

Maculaser

Announced that the company is now part of PhotonMed, a €32M EU-funded initiative to advance retinal care with photonics-based solutions. Through this collaboration, Maculaser will integrate photonic technologies into its treatment platform.

Nalu Medical

Received FDA clearance to expand MRI-conditional labeling for its peripheral nerve stimulation devices to include whole-body MRI compatibility. This milestone broadens the use of Nalu’s innovative technology by minimizing MRI-related restrictions.

Nina Capital

Announced that LSI Alumni Nadin Youssef was promoted to Associate at Nina Capital. Youssef’s dedication and contributions have been instrumental to Nina Capital’s continued success in supporting need-driven health tech founders.

Novuson Surgical

Appointed Mart Pearson as its Executive Vice President of Business Development. Pearson brings over three decades of medical device commercialization experience and will play a pivotal role in driving the commercialization of Novuson’s Direct Therapeutic Ultrasound technology.

NOxy Health Products

Appointed Sarah Griffiths as its Chief Scientific Officer. Griffiths will accelerate the clinical development of NOX1416, the company’s topical nitric oxide drug for chronic wounds, and expand real-world data for NOxyDERM.

Pulse Biosciences

Presented late-breaking data from its first-in-human feasibility study of the Nanosecond Pulsed-Field Ablation 360° Cardiac Catheter System for treating atrial fibrillation. Results from the first 30 patients showed strong pulmonary vein isolation with short case times.

Synergia Medical

Implanted its NAO.VNS system in three additional patients as part of the AURORA study, bringing the total to five. The company also announced that Charles Nolet will succeed Attila Borbath as CEO, effective February 1, 2025.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.